Monoclonal Antibody Therapeutics Market by Source (Human, Humanized, Chimeric, Other Sources), Therapy Area, Route of Administration, Production Method, End User, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030

Monoclonal Antibody Therapeutics Market by Source (Human, Humanized, Chimeric, Other Sources), Therapy Area, Route of Administration, Production Method, End User, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030

Monoclonal Antibody Therapeutics Market Size

The global monoclonal antibody therapeutics market size was valued at $247.35 billion in 2024 and is projected to reach $572.13 billion by 2030, growing at a CAGR of 15.0% during the forecast period.

Monoclonal Antibody Therapeutics Market Overview

Monoclonal antibody therapeutics involve the use of lab-created antibodies designed to target specific proteins in the body, playing a crucial role in treating various diseases, including cancers, autoimmune disorders, and infections. These antibodies are engineered to bind with high specificity to particular antigens found on the surface of cells or pathogens, blocking harmful interactions or marking the target for destruction by the immune system. The process begins by identifying the appropriate antigen, followed by producing identical (monoclonal) antibodies through cell lines derived from a single immune cell. This precision allows for targeted therapy, reducing the risk of damage to healthy cells and improving the efficacy and safety profiles of treatments. Monoclonal antibodies have revolutionized medicine by providing tailored, effective solutions for conditions that were previously difficult to manage.

Monoclonal Antibody Therapeutics Market Dynamics

• The monoclonal antibody therapeutics market is expected to witness significant growth in the future due to the increasing prevalence of chronic diseases such as cancer and autoimmune disorders and the advancements in biotechnology and genetic engineering.
• Additionally, the growing approval and adoption of monoclonal antibody therapies and the rising investment in healthcare and pharmaceutical R&D are the prominent factors driving the growth of the monoclonal antibody therapeutics market.
• However, the high cost of monoclonal antibody production and treatment and the stringent regulatory requirements and lengthy approval processes are restraining the market growth.
• On the contrary, the development of novel monoclonal antibodies for untapped therapeutic areas and the advances in personalized medicine and companion diagnostics are creating opportunities for market growth.

By End User, the Hospitals Segment held the Larger Market Share, and it would continue on this Path during the Forecast Period

The hospitals segment dominated the market share and is expected to maintain its leading position throughout the forecast period owing to their effectiveness in treating a range of serious and complex conditions, including cancers, autoimmune diseases, and infectious diseases. Hospitals are increasingly adopting these therapies because they offer targeted treatment options that can significantly improve patient outcomes compared to traditional therapies. Monoclonal antibodies can precisely target diseased cells while sparing healthy ones, leading to fewer side effects and better tolerability. Additionally, the rise in hospital admissions for chronic diseases and the need for specialized treatments that can be administered under medical supervision contribute to the growing demand. As these therapies often require careful monitoring and management, hospitals are the ideal setting for their administration, further fueling their popularity in this segment. The ongoing advancements in biotechnology and the increasing number of FDA approvals for new monoclonal antibody treatments also support their expanded use in hospital settings, providing healthcare providers with a broader arsenal of effective therapeutic options.

By Geography, North America Dominates by Being the Largest Market for Monoclonal Antibody Therapeutics

The North America leads as the primary market for monoclonal antibody therapeutics during the forecast period due to the region's advanced healthcare infrastructure and high healthcare expenditure. North America, particularly the United States, has a high prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, driving the need for effective therapeutic options like monoclonal antibodies. Additionally, robust research and development activities, supported by substantial funding from both government and private sectors, contribute to the rapid development and approval of new monoclonal antibody therapies. The presence of leading biopharmaceutical companies and academic institutions further accelerates innovation and availability of these treatments. Furthermore, favorable regulatory frameworks and expedited approval processes by agencies such as the FDA facilitate quicker access to the latest monoclonal antibody therapies, ensuring that patients benefit from the most advanced treatments available.

Key Target Audience:

• Pharmaceutical and Biotechnology Companies
• Healthcare Providers
• Patients With Chronic and Complex Diseases
• Regulatory Bodies (FDA, EMA, etc)
• Research and Academic Institutions
• Health Insurance Providers
• Investors and Venture Capitalists
• Contract Research Organizations (CROs)
• Contract Manufacturing Organizations (CMOs)

List of the Key Players Profiled in the Report Includes:

• Abbvie Inc
• Amgen Inc.
• AstraZeneca
• Biogen
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Sanofi
• UCB S.A

Recent Developments:

• In January 2024, UCB Inc. obtained U.S. FDA approval for RYSTIGGO (rozanolixizumab-noli) to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

Market Segmentation:

The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Source:

• Human
• Humanized
• Chimeric
• Other Sources

Market by, Therapy Area:

• Autoimmune & Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Other Therapy Areas

Market by, Route of Administration:

• Intravenous
• Subcutaneous
• Other Route of Administrations

Market by, Production Method:

• In-Vitro
• In-Vivo

Market by, End User:

• Hospitals
• Long-term Care Facilities
• Other End Users

Market by, Geography:

The monoclonal antibody therapeutics market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:

• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

Scope of the Report:

The report “Global Monoclonal Antibody Therapeutics Market: Industry Analysis, Opportunities and Forecast up to 2030” by Diligence Insights provides a detailed analysis of the present market and future outlook with market estimates and forecasts for all specified segments, encompassing both global and regional perspectives as outlined within the research framework. The study includes historical market data for the years 2022, 2023 and offers revenue estimations for 2024, and project forecasts spanning from 2025 to 2030. It places significant emphasis on the examination of market trends, key industry participants, supply chain developments, technological advancements, pivotal milestones, and prospective strategies. Comprehensive market assessments are carried out across major geographic regions, including North America, Europe, Asia Pacific, South America, and Middle East & Africa. As such, this report constitutes a valuable resource for current industry stakeholders, newcomers to the field, and potential investors.

The study offers an in-depth market analysis, drawing insights from industry experts across the value chain. A special focus has been made on 25 countries, including the United States, Canada, Mexico, the United Kingdom, Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, and South Africa, among others. The market data has been meticulously collected through extensive primary interviews and comprehensive secondary research. Market size determination is rooted in the revenue generated from sales across all the specified segments and sub-segments as defined within the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

The report offers insights into the following aspects:

• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.